Abstract:161Tb is an interesting radionuclide for application in the treatment of neuroendocrine neoplasms' small metastases and single cancer cells because of its conversion and Auger-electron emission. Tb has coordination chemistry similar to that of Lu; therefore, like 177Lu, it can stably radiolabel DOTATOC, one of the leading peptides used for the treatment of neuroendocrine neoplasms. However, 161Tb is a recently developed radionuclide that has not yet been specified for clinical use. Therefore, the aim of the current work was to characterize and specify 161Tb and to develop a protocol for the synthesis and quality control of 161Tb-DOTATOC with a fully automated process conforming to good-manufacturing-practice guidelines, in view of its clinical use. Methods: 161Tb, produced by neutron irradiation of 160Gd in high-flux reactors followed by radiochemical separation from its target material, was characterized regarding its radionuclidic purity, chemical purity, endotoxin level, and radiochemical purity (RCP) in analogy to what is described in the European Pharmacopoeia for no-carrier-added 177Lu. In addition, 161Tb was introduced into a fully automated cassette-module synthesis to produce 161Tb-DOTATOC, as used for 177Lu-DOTATOC. The quality and stability of the produced radiopharmaceutical in terms of identity, RCP, and ethanol and endotoxin content were assessed by means of high-performance liquid chromatography, gas chromatography, and an endotoxin test, respectively. Results: 161Tb produced under the described conditions showed, as the no-carrier-added 177Lu, a pH of 1-2, radionuclidic purity and RCP of more than 99.9%, and an endotoxin level below the permitted range (175 IU/mL), indicating its appropriate quality for clinical use. In addition, an efficient and robust procedure for the automated production and quality control of 161Tb-DOTATOC with clinically applicable specifications and activity levels, that is, 1.0-7.4 GBq in 20 mL, was developed. The radiopharmaceutical's quality control was also developed using chromatographic methods, which confirmed the product's stability (RCP ≥ 95%) over 24 h. Conclusion: The current study demonstrated that 161Tb has appropriate features for clinical use. The developed synthesis protocol guarantees high yields and safe preparation of injectable 161Tb-DOTATOC. The investigated approach could be translated to other DOTA-derivatized peptides; thus, 161Tb could be successfully applied in clinical practice for radionuclide therapy.

Phase I Clinical Study with Different Doses of 99Mtc-Trodat-1 in Healthy Adults.

Imaging Study of Brain Dopamine Transporter Imaging Agent ~(99)Tc~m-Trodat-1

Pharmacokinetics and Radiation Dosimetry of Tc-99m-3prgd(2) in Healthy Individuals: A Pilot Study

Investigating the Role of 99Mtc-Trodat-1 SPECT Imaging in Idiopathic Parkinson's Disease.

Study on ~(99M)tc-Trodat-1 SPECT in Diagnosis of Early Parkinson's Disease

The Study of Labelling of Dopamine Transporter Imaging Agent ~(99)Tc~m-Trodat-1

Phase IV clinical trial of 99Tcm-tetrofosmin injection: safety and efficiency for myocardial perfusion imaging

Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans

161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic

Establishing Updated Safety Standards for Independent 99mTc-MAA SPECT/CT Treatment Planning in Radioembolization

Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer

Study on pharmacokinetics and acute toxicity of new molecular probe 99 m Tc-RRL

Phase I Safety, Tolerability, And Pharmacokinetic Studies Of Tetramethylpyrazine Nitrone In Healthy Chinese Volunteers

An Exploratory Study on 99Mtc-Rgd-bbn Peptide Scintimammography in the Assessment of Breast Malignant Lesions Compared to 99Mtc-3P4-rgd2.

Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting

Synthesis and initial evaluation of radioiodine-labelled deuterated tropane derivatives targeting dopamine transporter

Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [ 177 Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

99Mtc-Trodat-1 SPECT Study in Early Parkinson's Disease and Essential Tremor.

Prognostic Value Oftc99m-Pertechnetate Thyroid Scintigraphy in Radioiodine Therapy in a Cohort of Chinese Graves’ Disease Patients: A Pilot Clinical Study

Study on Pharmacokinetics and Acute Toxicity of Human Telomerase Reverse Transcriptase Antisense Oligonucleotide Molecular Probe